ESTEVE’S R&D, AGAIN RATED ’EXCELLENT’ BY PROFARMA PLAN
The Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) of the Ministry of Industry, Energy and Tourism has one more year rated ESTEVE's R&D activities as 'excellent'. This is the 29th consecutive time that our laboratory receives this seal of quality, ever since the launch of Profarma in 1986.
ESTEVE is classified in Group A of the Proforma Plan (2013-2016), which includes pharmaceutical companies with significant research activities that have their own production center or basic or preclinical R&D.
Innovation and internationalization are two strategic axes at ESTEVE, a company that invests 63 million Euros a year in research and has a workforce of 2,279 professionals, 10% of which devoted exclusively to R&D activities. This firm commitment and effort have again resulted in the annual renovation of the maximum rating granted by Profarma, an official seal of quality that fosters R&D in the pharmaceutical sector.
You can follow ESTEVE on Twitter at this link: twitter.com/esteve_news.
ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE
Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europeread more
POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN
The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugsread more
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more